[Are monamine oxidase inhibitors in disposition to malignant hyperthermia contraindicated? Discussion based on a case report].
We report on a young patient with a positive family history for malignant hyperthermia (MH), who was diagnosed as susceptible to MH in our malignant hyperthermia laboratory by the in vitro-contracture test. Prior to the investigation of MH-susceptibility, the patient had been on medication with moclobemide, a monoamine oxidase (MAO) inhibitor, over a period of 13 months for treatment of a hyperactivity disorder. During the therapy with moclobemide no signs of relevant side effects were observed. However, some authors regard MAO-inhibitors as MH-triggering agents. The risk of MH-patients due to the therapy with MAO-inhibitors and the association between MH and the neuroleptic malignant syndrome is discussed in this case report.
Wappler
F
F
Abteilung für Anästhesiologie, Universitäts-Krankenhaus Eppendorf, Hamburg.
Köchling
A
A
Roewer
N
N
D018685:Anesthetics, Inhalation; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D001549:Benzamides / Q000008:administration & dosage; D002648:Child; D000075202:Contraindications; D004305:Dose-Response Relationship, Drug; D006221:Halothane; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008305:Malignant Hyperthermia / Q000235:genetics*; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage; D009119:Muscle Contraction / Q000187:drug effects; D012307:Risk Factors
D018685:Anesthetics, Inhalation; D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D020912:Moclobemide; D006221:Halothane
Sind Monoaminoxidase-Hemmstoffe bei Disposition zu maligner Hyperthermie kontraindiziert? Diskussion anhand eines Fallberichts.